Facioscapulohumeral Muscular Dystrophy

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 601-606

  Tawil, Rabi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

chromosome 4; facioscapulohumeral muscular dystrophy; FSHD; muscular dystrophy; myostatin

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CREATINE; CYANOCOBALAMIN; FOLIC ACID; METHIONINE; MONOCLONAL ANTIBODY; MYO 029; NONSTEROID ANTIINFLAMMATORY AGENT; SALBUTAMOL; UNCLASSIFIED DRUG;

ARTICLE; ASSISTIVE TECHNOLOGY DEVICE; BECKER MUSCULAR DYSTROPHY; DIAGNOSTIC PROCEDURE; EXERCISE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FOOT ORTHOSIS; GENETIC DISORDER; HEARING LOSS; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; NONHUMAN; PAIN; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETINA DISEASE; RETINA TELANGIECTASIA; SCAPULAR FIXATION; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE;

ANIMALS; HUMANS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOSTATIN; STEM CELL TRANSPLANTATION;

EID: 53049110907     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.07.005     Document Type: Article

References (65)

1. Padberg G.W. Facioscapulohumeral disease. Thesis (1982), University of Leiden, Leiden, The Netherlands
2. Wohlgemuth M., van der Kooi E.L., van Kesteren R.G., van der Maarel S.M., and Padberg G.W. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 63 (2004) 176-178
3. Fitzsimons R.B., Gurwin E.B., and Bird A.C. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy: a general association with genetic and therapeutic implications. Brain 110 (1987) 631-648
4. Padberg G.W., Brouwer O.F., de Keizer R.F., et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve (1995) S73-S80
5. Shields C.L., Zahler J., Falk N., et al. Neovascular glaucoma from advanced Coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol 125 (2007) 840-842
6. Laforêt P., de Toma C., Eymard B., et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 51 (1998) 1454-1456
7. Wijmenga C., Hewitt J.E., Sandkuijl L.A., et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 2 (1992) 26-30
8. Lunt P.W., Jardine P.E., Koch M.C., et al. Correlation between fragment size at D4F104S1 and age of onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) [Erratum in: Hum Mol Genet 1995;4:1243-1244]. Hum Mol Genet 4 (1995) 951-958
9. Tawil R., Forrester J., Griggs R.C., et al., The FSH-DY Group. Evidence for anticipation and association of deletion size with severity of facioscapulohumeral muscular dystrophy. Ann Neurol 39 (1996) 744-748
10. Tupler R., Berardinelli A., Barbierato L., et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet 33 (1996) 366-370
11. Lyle R., Wright T.J., Clark L.N., and Hewitt J.E. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics 28 (1995) 389-397
12. Gabriëls J., Beckers M.C., Ding H., et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236 (1999) 25-32
13. Hewitt J.E., Lyle R., Clark L.N., et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 3 (1994) 1287-1295
14. Clapp J., Mitchell L.M., Bolland D.J., et al. Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am J Hum Genet 81 (2007) 264-279
15. van Deutekom J.C.T., Lemmers R.J.L.F., Grewal P.K., et al. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum Mol Genet 5 (1996) 581-590
16. Grewal P.K., Todd L.C., van der Maarel S., Frants R.R., and Hewitt J.E. FRG1, a gene in the FSH muscular dystrophy region on human chromosome 4q35, is highly conserved in vertebrates and invertebrates. Gene 216 (1998) 13-19
17. van Koningsbruggen S., Dirks R.W., Mommaas A.M., et al. FRG1P is localised in the nucleolus, Cajal bodies, and speckles. J Med Genet 41 (2004) e46
18. Gabellini D., Green M., and Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110 (2002) 339-348
19. Jiang G., Yang F., van Overveld P.G., Vedanarayanan V., van der Maarel S., and Ehrlich M. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q. Hum Mol Genet 12 (2003) 2909-2921
20. Winokur S.T., Chen Y.W., Masny P.S., et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet 12 (2003) 2895-2907
21. Osborne R.J., Welle S., Venance S.L., Thornton C.A., and Tawil R. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68 (2007) 569-577
22. Masny P.S., Bengtsson U., Chung S.A., et al. Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?. Hum Mol Genet 13 (2004) 1857-1871
23. de Greef J.C., Wohlgemuth M., Chan O.A., et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology 69 (2007) 1018-1026
24. Petrov A., Allinne J., Pirozhkova I., Laoudj D., Lipinski M., and Vassetzky Y.S. A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy. Genome Res 18 (2008) 39-45
25. Orrell R.W., Tawil R., Forrester J., Kissel J.T., Mendell J.R., and Figlewicz D.A. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology 52 (1999) 1822-1826
26. van Deutekom J.C., Bakker E., Lemmers R.J., et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet 5 (1996) 1997-2003
27. Bushby K.M., Pollitt C., Johnson M.A., Rogers M.T., and Chinnery P.F. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord 8 (1998) 574-579
28. Fitzsimons R.B. Retinal vascular abnormalities in FSHD: a therapeutic message; clues to pathogenesis. In: Upadhyaya M., and Cooper D.N. (Eds). Facioscapulohumeral muscular dystrophy (FSHD): clinical medicine and molecular cell biology (2004), BIOS Scientific Publishers, New York 185-195
29. McCartney N., Moroz D., Garner S.H., and McComas A.J. The effects of strength training in patients with selected neuromuscular disorders. Med Sci Sports Exerc 20 (1988) 362-368
30. Milner-Brown H.S., and Miller R.G. Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 69 (1988) 14-19
31. Vignos Jr. P.J., and Watkins M.P. The effect of exercise in muscular dystrophy. JAMA 197 (1966) 843-848
32. Olsen D.B., Ørngreen M.C., and Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology 64 (2005) 1064-1066
33. van der Kooi E.L., Vogels O.J., van Asseldonk R.J., et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63 (2004) 702-708
34. Bunch W.H., and Siegel I.M. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy: review of seventeen procedures with three to twenty-one-year follow up. J Bone Joint Surg Am 75 (1993) 372-376
35. Copeland S.A., Levy O., Warner G.C., and Dodenhoff R.M. The shoulder in patients with muscular dystrophy. Clin Orthop 368 (1999) 80-91
36. Giannini S., Faldini C., Pagkrati S., et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. Clin Med Res 5 (2007) 155-162
37. Rhee Y.G., and Ha J.H. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. J Shoulder Elbow Surg 15 (2006) 445-450
38. Mummery C.J., Copeland S.A., and Rose M.R. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev 3 (2003) CD003278
39. Wolfe G.I., Young P.K., Nations S.P., Burkhead W.Z., McVey A.L., and Barohn R.J. Brachial plexopathy following thoracoscapular fusion in facioscapulohumeral muscular dystrophy. Neurology 64 (2005) 572-573
40. Mackenzie W.G., Riddle E.C., Earley J.L., and Sawatzky B.J. A neurovascular complication after scapulothoracic arthrodesis. Clin Orthop Relat Res 408 (2003) 157-161 Mar
41. Sansone V., Boynton J., and Palenski C. Use of gold weights to correct lagophthalmos in neuromuscular disease. Neurology 48 (1997) 1500-1503
42. Munsat T.L., Piper D., Cancilla P., and Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology 22 (1972) 335-347
43. Bates D., Stevens J.C., and Hudgson P. "Polymyositis" with involvement of facial and distal musculature: one form of the facioscapulohumeral syndrome?. J Neurol Sci 19 (1973) 105-108
44. Wulff J.D., Lin J.T., and Kepes J.J. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann Neurol 12 (1982) 398-401
45. Tawil R., McDermott M.P., Pandya S., et al., The FSH-DY Group. A pilot study of prednisone in facioscapulohumeral muscular dystrophy. Neurology 48 (1997) 46-49
46. Benson D.W., Foley-Nelson T., Chance W.T., Zhang F.S., James J.H., and Fischer J.E. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50 (1991) 1-5
47. Matlin C.A., Hay S.M., McMillan D.N., and Delday M.I. Tissue specific responses to clenbuterol; temporal changes in protein metabolism of striated muscle and visceral tissues from rats. Growth Regul 2 (1992) 161-166
48. Agbenyega E.T., and Wareham A.C. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 102 (1992) 141-145
49. Choo J.J., Horan M.A., Little R.A., and Rothwell N.J. Muscle wasting associated with endotoxemia in the rat: modification by the β2-adrenoceptor agonist clenbuterol. Biosci Rep 9 (1989) 615-621
50. Hayes A., and Williams D.A. Examining the potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol. J Neurol Sci 157 (1998) 122-128
51. Zeman R.J., Ludemann R., and Etlinger J.D. Clenbuterol, a β2 agonist, retards atrophy in denervated muscles. Am J Physiol 252 (1987) E152-E155
52. Martineau L., Horan M.A., Rothwell N.J., and Little R.A. Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men [Erratum in: Clin Sci 1993;84(6):following XX]. Clin Sci (Lond) 83 (1992) 615-621
53. Kissel J.T., McDermott M.P., Mendell J.R., et al., The FSH-DY Group. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 57 (2001) 1434-1440
54. Kemp G.J., Taylor D.J., Dunn J.F., Frostick S.P., and Radda G.K. Cellular energetics of dystrophic muscle. J Neurol Sci 116 (1993) 201-206
55. 2+ handling and survival in mdx skeletal muscle cells. GEBS Lett 439 (1998) 357-362
56. Walter M.C., Lochmüller H., Reilich P., et al. Creatine monohydrate in muscular dystrophies: a double-blind placebo controlled clinical study. Neurology 54 (2000) 1848-1850
57. Rose M.R., and Tawil R. Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database Syst Rev 2 (2004) CD002276
58. Patel K., and Amthor H. The function of myostatin and strategies of myostatin blockade: new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 15 (2005) 117-126
59. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63 (2008) 561-571
60. van Overveld P.G., Enthoven L., Ricci E., et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 58 (2005) 569-576
61. van der Kooi E.L., de Greef J.C., Wohlgemuth M., et al. No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 16 (2006) 766-769
62. Lee S.J., Reed L.A., Davies M.V., et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 102 (2005) 18117-18122
63. Lachey J., Pullen A., Pearsall R., and Seehra J. Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice. Neuromuscul Disord 17 (2007) 785 abstract
64. Vilquin J.T., Marolleau J.P., Sacconi S., et al. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Gene Ther 12 (2005) 1651-1662
65. Morosetti R., Mirabella M., Gliubizzi C., et al. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Stem Cells 25 (2007) 3173-3182